EGFR and non-small cell lung carcinoma: Recently, a phase II trial in patients with advanced NSCLC also demonstrated that cetuximab plus chemotherapy improved progression-free survival (PFS) and OS in EGFR FISH-positive patients compared with those who were FISH-negative.19 These results suggest that an assay to determine EGFR FISH status may be applicable for selection of patients for anti-EGFR therapies, although prospective validation of these results is warranted before the use of the marker is implemented for patient management.